Core Insights - Clarivate Plc has renewed its partnership with CAPES, significantly expanding access to academic and life sciences data across over 400 Brazilian institutions, increasing institutional coverage by 57% compared to the previous contract [1][2][6] - The partnership aims to democratize access to critical scientific information, enabling researchers and practitioners to conduct innovative research and improve patient care [3][4][6] - The agreement enhances access to various research tools, including Web of Science, Journal Citation Reports, and Cortellis Drug Discovery Intelligence, supporting evidence-based discovery and decision-making [2][5][6] Company and Industry Impact - The collaboration with CAPES reflects a commitment to advancing scientific excellence and reducing regional disparities in Brazil's research landscape [4][6] - The expanded access to trusted research tools is expected to strengthen postgraduate programs and elevate the global visibility of Brazilian research [6][7] - Brazil's research output shows a strong focus on Sustainable Development Goals, particularly in Life Sciences and Medicine, with a notable emphasis on international collaboration [10]

Q1 2025 Financial Performance - Revenues reached $594 million[13], a decrease of $27 million compared to Q1 2024[39] - Adjusted EBITDA was $233 million[15], with a 39% margin[16], representing a 130 bps increase year-over-year[16] - Free Cash Flow was $110 million[16], flat compared to the previous year[16], with a 47% conversion rate[16] - Adjusted Diluted EPS was $0.14[19], consistent with the prior year[39] Key Business Highlights - Academia & Government sector saw early success with a new Web of Science commercial model, securing multiyear deals totaling over $80 million TCV[17] - Life Sciences & Healthcare achieved a 90% renewal rate, a 3% increase year-over-year[17] - Recurring organic revenue growth was 0.6%[14], driven by a return to growth in patent renewal volumes[40] - The renewal rate was 94%[14], up 1% year-over-year[14] FY 2025 Guidance - The company expects revenues of approximately $2340 million[54] - Adjusted EBITDA is projected to be around $970 million[54], with a margin of approximately 41.5%[54] - Free Cash Flow is anticipated to be about $340 million[54] - Recurring revenue mix is expected to improve by approximately 5% due to strategic disposals[56]